With headquarters in Montréal, Canada, Paladin Pharma Inc. is a leading specialty pharmaceutical company focused on acquiring or licensing emerging pharmaceuticals for the Canadian market.
Its dedicated employees have propelled Paladin to become one of Canada’s pioneers in specialty pharmaceuticals.
Paladin is an operating company of Endo, Inc. a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients through excellence in development, manufacturing and commercialization.
29-Jun-2023
Endo Announces Approval of XCOPRI™ (cenobamate tablets) in Canada
17-Jan-2022
Paladin Labs Inc. Announces the Launch of Xydalba® (dalbavancin for injection) in Canada
09-Jun-2021
Paladin Labs Inc. Announces Approval of Wakix® (pitolisant) in Canada
05-Jan-2021
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada
31-Jul-2019
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
10-Jun-2015
ARIAD and Paladin Announce Commercial Distribution Agreement for Iclusig (Ponatinib) in Canada
9- Feb- 2015
Paladin Labs Announces the Canadian Launch of Zincofax® Spray
19-Aug-2013
Paladin Labs Announces the Canadian Launch of Emtrix®
For complete list of press releases click Here.